Why Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 7, 2023

In this episode of The HemOnc Pulse, Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma (DLBCL).

“The last couple of years, we’ve seen quite a revolution in the treatment of DLBCL,” he said. “We have multiple approved therapies now, and more coming, so it’s really a very rapidly changing field.”

He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab-cxix in combination with lenalidomide.

“What’s interesting about this combination is that those responses were durable, there is [approximately] 40% patients in very durable remissions still after the initial treatment, which we had not seen before with chemotherapy,” he said.

The L-MIND study showed that tafasitamab-cxix plus lenalidomide followed by tafasitamab-cxix monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory DLBCL.

The data from the study were presented at the 2023 American Association for Cancer Research Annual Meeting, held April 14-19 in Orlando, Florida.

Find all episodes of The HemOnc Pulse here.

Editorial Board